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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.020Fas-induced apoptosis is involved in diverse liver diseases. Herein, we investigated the effect of Mir155
deletion on Fas-induced liver injury. Wild-type (WT) mice and Mir155 knockout (KO) mice were i.p.
administered with the anti-Fas antibody (Jo2) to determine animal survival and the extent of liver injury.
After Jo2 injection, the Mir155 KO mice exhibited prolonged survival versus the WT mice (P < 0.01). The
Mir155 KO mice showed lower alanine aminotransferase and aspartate aminotransferase levels, less liver
tissue damage, fewer apoptotic hepatocytes, and lower liver tissue caspase 3/7, 8, and 9 activities
compared with the WT mice, indicating that Mir155 deletion prevents Fas-induced hepatocyte apoptosis
and liver injury. Hepatocytes isolated from Mir155 KO mice also showed resistance to Fas-induced
apoptosis, in vitro. Higher protein level of myeloid cell leukemia-1 (Mcl-1) was also observed in Mir155
KO hepatocytes compared to WT hepatocytes. A miR-155 binding site was identiﬁed in the 30-untranslated
region of Mcl-1 mRNA; Mcl1 was identiﬁed as a direct target of miR-155 in hepatocytes. Consistently,
pretreatment with a siRNA speciﬁc for Mcl1 reversed Mir155 deletionemediated protection against Jo2-
induced liver tissue damage. Finally, restoration of Mir155 expression in Mir155 KO mice abolished the
protection against Fas-induced hepatocyte apoptosis. Taken together, these ﬁndings demonstrate that
deletion of Mir155 prevents Fas-induced hepatocyte apoptosis and liver injury through the up-regulation
of Mcl1. (Am J Pathol 2015, 185: 1033e1044; http://dx.doi.org/10.1016/j.ajpath.2014.12.020)Supported by NIH grants CA106280, CA102325, CA134568, and
DK077776 (T.W.).
Disclosures: None declared.miRNAs are a class of small noncoding RNAs that regulate
gene expression through binding to speciﬁc sequences of their
targetedmRNAs.1miR-155was initially identiﬁed as a speciﬁc
miRNA for hematopoietic and immune cells and is among
the ﬁrst miRNAs linked to immunity and inﬂammation.2e4
Indeed, miR-155 has been shown to modulate the production
of cytokines in various immune cells; the expression ofMir155
is up-regulated inmultiple immune cell lineages on stimulation
with Toll-like receptor ligands, inﬂammatory cytokines, and
speciﬁc antigens.5e9 Subsequent studies have shown thatmiR-
155 also mediates functions outside the hematopoietic and
immune systems.10,11 In the liver, miR-155 has been shown to
play a role in hepatocarcinogenesis,12e15 although its mecha-
nism of action remains to be further deﬁned. miR-155 has also
been shown to contribute to alcohol-induced liver injury
through induction of tumor necrosis factor a production in
macrophages.16 Interestingly, the level ofmiR-155 is increased
in serum and plasma in patients with alcoholic and inﬂamma-
tory liver injuries.17,18 These observations suggest a potentialstigative Pathology.
.role of miR-155 in liver injury and liver diseases. However, at
present, the biological functions and mechanisms of miR-155
in liver cells have not been delineated.
The current study aimed to determine the effect and
mechanism of miR-155 in Fas and lipopolysaccharide
(LPS)/D-galactosamine (D-GalN)emediated liver injury in
mice. Our data show that deletion ofMir155 protects against
Fas-induced hepatocyte apoptosis and liver injury but not
LPS/D-GalNeinduced liver injury. The role of miR-155 in
hepatocytes was demonstrated by in vitro studies using
hepatocytes isolated from Mir155 knockout (KO) mice.
Myeloid cell leukemia-1 (Mcl-1) was identiﬁed as a direct
target of miR-155 in hepatocytes. Our results reveal a novel
role of miR-155 in hepatocytes for regulation of Mcl1 and
protection against Fas-induced apoptosis.
Chen et alMaterials and Methods
Animals
C57BL/6 wild-type (WT) mice and Mir155 KO mice were
obtained from the Jackson Laboratory (Bar Harbor, ME).
The mice were maintained at 22C under a 12-hour light/
dark cycle and received food and water freely at the Tulane
University Health Sciences Center Animal Facility (New
Orleans, LA). The experimental procedures were performed
according to the guidelines of the Institutional Animal Care
and Use Committee of Tulane University.Experimental Protocol
Male C57BL/6WT andMir155KOmice were used at the age
of 8 weeks. For survival experiments, the mice were injected
i.p. with 0.35 mg/g of body weight Jo2 anti-Fas antibody (BD
Bioscience, Franklin Lakes, NJ). Jo2 was dissolved in a sterile
1 Dulbecco’s phosphate-buffered saline (PBS; Sigma-
Aldrich, St. Louis, MO). The animals were observed continu-
ously for up to 24 hours after Jo2 injection and the time of death
was recorded. To assess the extent of Jo2-induced liver injury,
the mice were i.p. administered 0.5 mg/g of body weight
Jo2 and the animals were sacriﬁced at speciﬁc time points.
The liver tissues were rapidly excised, and the specimens
were immediately cut into small fragments and subjected to
standard formalin ﬁxation and parafﬁn embedding for histo-
logical evaluation and terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate digoxigenin nick-end
labeling (TUNEL). The remaining liver tissues were immedi-
ately frozen in liquid nitrogen and stored at 80C. Blood
sample was collected from mouse orbital and centrifuged at
800 g for 15minutes. Serumalanine aminotransferase (ALT)
and aspartate aminotransferase (AST) activitiesweremeasured
with an automatic analyzer at the Department of Clinical
Chemistry, Tulane University Hospital.
In separate experiments, 8-week-oldmale C57BL/6WT and
Mir155 KO mice were pretreated with 7 mg/kg Mcl1 siRNA
(Invitrogen, Grand Island, NY) or 7 mg/kg siRNA control
(Invitrogen) via tail vein injection (theMcl1 siRNA and control
siRNA were speciﬁcally designed for in vivo study). Invivo-
fectamine 2.0 reagent (Invitrogen) was used for optimal de-
livery to the liver (the Invivofectamine-siRNA complex was
prepared according to the manufacturer’s instruction). At 48
hours after injection of the Invivofectamine-siRNA complex,
themice were injectedwith Jo2 via 0.5mg/g of bodyweight i.p.
injection. The mice were sacriﬁced 4 hours after Jo2 injection,
and the liver tissues and blood samples were collected.
To restore Mir155 expression in Mir155 KO mice, we ob-
tained puriﬁed lentiviral particles containing pre-Mir155 or
scrambled controlmiRNAfromGeneCopoeia (Rockville,MD).
Eight-week-old male Mir155 KO mice were administrated
lentiviral particles containing preemiR-155 (LV-miR-155;
2.53  109 copies per mouse) or lentiviral particles containing
scrambled miRNA (LV-scrambled-miRNA; 4.8  108 copies1034permouse) by tail vein injection in a volume of 200 mL of sterile
saline. One week after virus injection, the mice were i.p.
administered 0.5 mg/g of body weight Jo2. The mice were
sacriﬁced 4 hours after Jo2 injection, and the liver tissues and
blood samples were collected for further analyses.
To determine the LPS/D-GalNeinduced liver injury
model, 8-week-old male C57BL/6 WT andMir155 KO mice
were administered i.p. with 25 ng/g body weight LPS
(Escherichia coli O55:B6; Sigma-Aldrich) in combination
with 600 mg/g body weight of D-GalN (Sigma-Aldrich). LPS
and D-GalN were dissolved in sterile, nonpyrogenic, 0.9%
sodium chloride injection. The mice were sacriﬁced 4 hours
after LPS andD-GalN administration to obtain blood and liver
tissues.
Hematoxylin and Eosin Staining
Liver tissues were excised and ﬁxed in 10% buffered formalin
and embedded in parafﬁn. Sections (5 mm thick) were afﬁxed
to slides; the sections were deparafﬁnized, and stained with
hematoxylin and eosin for histological evaluation.
TUNEL Assay
The DeadEnd Colorimetric TUNEL System (Promega
Corporation, Madison, WI) was used for the examination of
apoptotic cell death of the liver tissue. Slides with formalin-
ﬁxed sections (5 mm thick) were washed twice in xylene (5
minutes each time), hydrated in 100% ethanol for 2 minutes,
and washed in decreasing concentrations of ethanol (100%,
95%, and 80%; 2 minutes each time). The slides were then
immersed in water for 2 minutes and processed for TUNEL
staining, according to the manufacturer’s guidelines.
Immunohistochemical Analysis for Cleaved Caspase-3
Cleaved caspase-3 staining was performed by using a rabbit
polyclonal antibody against the large fragment (17/19 kDa)
of activated caspase-3 (Biocare Medical, Pike Lane
Concord, CA). Formalin-ﬁxed slides (5 mm thick) were
deparafﬁnized in xylene and hydrated in ethanol. The tissue
sections were processed for heat-induced epitope retrieval
under pressure by using a Decloaking Chamber (Biocare
Medical, Pike Lane Concord, CA). After blocking with
Peroxidazed (Biocare Medical) 1 for 5 minutes, the slides
were incubated with the antibody against cleaved caspase-3
at room temperature for 1 hour. The slides were then washed
with Tris-buffered saline and incubated with horseradish
peroxidaseeconjugated goat anti-rabbit IgG at room tem-
perature for 1 hour. After washing with Tris-buffered saline,
the slides were incubated for 5 minutes at room temperature
with 3,30-diaminobenzidine for chromogenic development.
Caspase Activity Analysis
Caspase 3/7, 8, and 9 activities were measured with
Caspase-Glo Assay kit (Promega Corporation). Liver tissueajp.amjpathol.org - The American Journal of Pathology
Mir155 Deletion Prevents Liver Injuryextracts were prepared by Dounce homogenization in hy-
potonic extraction buffer, as previously described.19
Quantitative Real-Time PCR
Total RNA was isolated from liver tissue by TRIzol (Invi-
trogen, Grand Island, NY). For ﬁrst-strand complementary
DNA synthesis, 1 mg total RNA was reverse transcribed
using Qiagen miScript reverse transcription kit (Qiagen,
Valencia, CA). Qiagen miScript SYBR Green PCR kit and
miR-155especiﬁc miScript Primer Assay were used to
amplify the mature form of miR-155 on Bio-Rad C1000
Thermal Cycler (Life Science, Hercules, CA). U6 (Qiagen)
was used as the internal control.
Isolation and Culture of Primary Mouse Hepatocytes
Hepatocytes were isolated from 8-week-old WT and Mir155
KO male mice by an adaptation of the calcium two-step
collagenase perfusion technique, as we described previ-
ously.20 Collagen Iecoated plates and dishes were purchased
formBDBiosciences (San Jose, CA).Hepatocytes (3 106 or
5  105) were plated onto collagen-coated, 10-cm dishes or
96-well plates, respectively. Hepatocytes were maintained in
Williams’ Medium E medium (Invitrogen) supplemented
with HepatocyteMaintenance Supplement Pack (Invitrogen),
10% fetal calf serum (Sigma-Aldrich), 2 mmol/L L-glutamine
(Invitrogen), and antibiotic-antimycotic (Invitrogen). After 2
hours to allow for attachment, the culture was washed with
PBS and the cells were incubated withmedium containing 0.1
mg/mL Jo2 plus 10 mg/mL cycloheximide. Four hours after
treatment, the cell lysates were obtained from 96-well plates
for caspase activity assay and from 10-cm dishes for Western
blot analysis.
Transfection and Luciferase Reporter Assay
The 30-untranslated region (UTR) of mouseMcl1 was cloned
downstream of the ﬁreﬂy luciferase reporter gene in pEZX-
MT01 vector (GeneCopoeia, Rockville, MD). Mutated
Mcl1 plasmid was constructed by using the Quick Change II
XL Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA). The primers used for the mutagenesis
were as follows: 50-TTAGTTATCTGCACGAGAACTC-
TCACCCCAAC-30 (forward) and 50-GTTGGGGTGAGA-
GTTCTCGTGCAGATAACTAA-30 (reverse). Hepatocytes
isolated from WT mice were plated onto collagen-coated,
6-well plates (BD Biosciences, San Jose, CA) at a density
of 1  106 cells per well; 2 hours after seeding, the hepato-
cytes were transfected with miR-155 mimic (Qiagen,
Valencia, CA) or control mimic (Qiagen) using Targefect F2
plus Virofect enhancer (Targetingsystems, El Cajon, CA).
Twelve hours after miR-155 mimic transfection, hepatocytes
were transfected withMcl1 30-UTR or control plasmid using
Targefect Hepatocyte Reagent (Targetingsystems). The he-
patocytes were harvested 24 hours after plasmid transfectionThe American Journal of Pathology - ajp.amjpathol.organd analyzed by using Dual-Luciferase reporter assay system
(Promega Corporation, Madison, WI). Luciferase reporter
activity was measured by centro xs3 lb 960 microplate ﬂuo-
rescence reader (Mandel, Guelph, ON, Canada).
Hoechst Staining
Hoechst 33,342 (Thermo Fisher Scientiﬁc, Waltham, MA)
was used to assess compacted nuclear chromatin and
apoptosis. WT hepatocytes and Mir155 KO hepatocytes
were plated onto collagen-coated, 6-well plates (BD Bio-
sciences) at a density of 1  106 cells per well. After 2 hours
of attachment, the hepatocytes were exposed to medium
with or without 0.1 mg/mL Jo2 plus 10 mg/mL cyclohexi-
mide for 4 hours. The cultures were then washed with PBS,
and the cells were incubated with Hoechst 33,342 (1 mg/mL
in 1 Dulbecco’s PBS) for 30 minutes at room temperature
in the dark. The nuclear morphological features were
observed at 200 magniﬁcation under ﬂuorescence micro-
scope using a wavelength of 460 to 490 nm.
Western Blot Analysis
To obtain liver tissue proteins, the liver tissues were lysed
with NP-40 lysis buffer [1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulfate, one tablet of protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), one
tablet of phosphatase inhibitor cocktail (Roche), and PBS,
pH 7.4]. The resulting liver homogenates were centrifuged
at 12,000  g for 20 minutes at 4C, and the supernatants
were collected for Western blot analysis. To isolate cell
lysates from cultured hepatocytes, the cells were washed
twice with ice-cold PBS and lysed in a lysis buffer con-
taining 50 mmol/L HEPES and 1 mmol/L EDTA (pH 8.0)
[one tablet of protease inhibitor cocktail (Roche) and one
tablet of phosphatase inhibitor cocktail (Roche) were added
per 10 mL buffer]. After sonication on ice, the cell lysates
were centrifuged at 12,000  g for 20 minutes at 4C and
the supernatants were collected for Western blot analysis.
The protein concentration was measured by using the Bio-
Rad Protein Assay Kit (Bio-Rad, Hercules, CA). After
boiling at 95C for 5 minutes in the protein loading buffer
with 2-mercaptoethanol, the samples were separated on a
10% SDS-PAGE gel. The separate proteins were then
transferred onto the nitrocellulose membrane (Bio-Rad).
After blocking in 5% nonfat milk (in 1 PBS) for 1 hour,
the membranes were incubated with primary antibodies in
5% nonfat milk (in 1 PBS) at 4C overnight. After three
washes with 0.1% Tween 20 in 1 PBS, the membranes
were incubated with secondary antibody (horseradish per-
oxidaseeconjugated IgG) in 5% nonfat milk (in 1 PBS) at
room temperature for 1 hour. The bands were analyzed by
LI-COR Odyssey (Lincoln, NE). Antibodies for Mcl-1, poly
(ADP-ribose) polymerase (PARP), caspase-3, cleaved cas-
pases 8 and 9, peglycogen synthetase kinase (GSK)e3b
(Ser9), p-Akt (Ser473), and Akt were obtained from Cell1035
Figure 1 Deletion of Mir155 protects mice
against Fas-induced liver injury. A: Survival curves
after 0.35 mg/g of body weight Jo2 treatment. B:
Wild-type (WT)andMir155 knockout (KO)micewere
i.p. injected with 0.5 mg/g of body weight Jo2, and
gross photographs of livers were taken 0, 2, and 4
hours after 0.5 mg/g of body weight Jo2 injection.
The mice used include the following: 24 mice per
group for 0 hours; 8 mice per group for 2 hours; and
24mice per group for 4 hours. The liver appearances
between WT and Mir155 KOmice at the 4-hour time
point were statistically different (dark red liver seen
in 18 of 24 WT mice and 8 of 24 Mir155 KO mice)
(P< 0.01, Fisher’s exact test). C: Hematoxylin and
eosin staining of liver sections at 0, 2, and 4 hours
after Jo2 injection. D: Serum levels of alanine
aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) in mice after Jo2 treatment. E: The
levels of miR-155 in the livers of WT mice and
Mir155 KO mice with or without 0.5 mg/g of body
weight Jo2 treatment, as determined by real-time
quantitative RT-PCR. Data are expressed as
means SD (D and E). nZ 8 (A and D). *P< 0.05,
**P< 0.01. Originalmagniﬁcation,100 (C). Con,
control.
Chen et alSignaling Technology (Beverly, MA); the antibody for GSK-
3b was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA); glyceraldehyde-3-phosphate dehydrogenase antibody
was purchased from Ambion (Austin, TX); and goat anti-
rabbit or goat anti-mouse second antibodies were pur-
chased from LI-COR Biosciences (Lincoln, NE).
Statistical Analysis
Data are presented as means  SD. Differences between the
two groups were determined by a two-tailed Student’s t-test.
Kaplan-Meier survival analysis (log rank) was used for
mortality analysis. P < 0.05 was considered statistically
signiﬁcant.1036Results
Mir155 KO Protects Mice against Fas-Induced Liver
Failure But Not LPS/D-GalNeInduced Liver Injury
To determine whether Mir155 may play a role in the
regulation of Fas-mediated apoptosis, 8-week-old male
C57BL/6 WT mice and Mir155 KO mice were injected i.p.
with a single dose of 0.35 mg/g of body weight Jo2. As
predicted, all of the WT mice rapidly died within 8 hours
after Jo2 challenge. In contrast, the Mir155 KO mice
showed prolonged survival and approximately 40% of
Mir155 KO mice remained alive (three of eight Mir155 KO
mice survived). The mortality of WT mice was signiﬁcantlyajp.amjpathol.org - The American Journal of Pathology
Figure 2 Deletion of Mir155 prevents Fas-induced caspase activation. WT (black bars) and Mir155 KO (white bars) mice were i.p. injected with 0.5 mg/g of body
weight Jo2 (nZ8per group).A: Caspase3/7, 8, and9activities in livers ofWTmice are signiﬁcantly higher than those inMir155KOmice after 4hours of Jo2 injection.B:
Western blot analysis to detect poly (ADP-ribose) polymerase (PARP) and caspase cleavage. C: Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphos-
phatedigoxigenin nick-end labeling (TUNEL) stainingof liver sections at 0, 2, and 4hours after Jo2 injection.D: The percentages of TUNEL-positive cells inWTandMir155
KOmice atdifferent times after Jo2 treatment.E: Liver tissue immunostain for cleavedcaspase-3 at0, 2, and4hours after Jo2 injection.Data are expressed asmeans SD
(A and D). nZ 8 (A); nZ 3 independent experiments (D). *P < 0.05, **P< 0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RLU, relative light unit.
Mir155 Deletion Prevents Liver Injuryhigher compared to the Mir155 KO mice (P < 0.01)
(Figure 1A). To further evaluate the degree of liver injury,
WT mice and Mir155 KO mice were injected with Jo2 at
0.5 mg/g of body weight dosage; the mice were thenThe American Journal of Pathology - ajp.amjpathol.orgsacriﬁced at speciﬁc time points (0, 2, and 4 hours after Jo2
injection) to obtain blood samples and liver tissues for liver
enzyme and histopathology analyses. The gross appearance
of the livers between WT and Mir155 KO mice did not1037
Figure 3 Deletion of Mir155 in hepatocytes protects against Fas-induced apoptosis. Primary hepatocytes were isolated from wild-type (WT; black bars)
mice and Mir155 knockout (KO; white bars) mice. A: The expression of miR-155 in hepatocytes was quantiﬁed by real-time quantitative RT-PCR. B: Cultured
hepatocytes were treated with 0.1 mg/mL Jo2 plus 10 mg/mL cycloheximide for 4 hours, and the cell lysates were obtained for Western blot analysis to
determine poly (ADP-ribose) polymerase (PARP) cleavage. C: Hoechst staining of cultured hepatocytes showing more prominent apoptosis in WT hepatocytes
compared to Mir155 KO hepatocytes after Jo2 treatment. D: Quantitative analysis for apoptotic cells under Hoechst staining. E: Caspase 3/7, 8, and 9 activity
assays were performed in cultured hepatocytes 4 hours after Jo2 treatment. Data are expressed as means  SD from three independent experiments (A, D, and
E). *P < 0.05, **P < 0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate-buffered saline.
Chen et aldiffer signiﬁcantly at 2 hours after Jo2 challenge. However,
at 4 hours after Jo2 treatment, the livers of WT mice turned
dark red because of massive hepatic hemorrhaging, whereas
the livers of Mir155 KO mice only showed slightly red
coloration (Figure 1B). These observations suggest that1038deletion of mir155 protects mice against Fas-induced liver
injury. Under histological examination, the WT livers
exhibited more prominent liver tissue injury with massive
hemorrhaging, congestion, hepatocyte apoptosis, and paren-
chymal dropout in contrast to the relatively mild liver injuryFigure 4 miR-155 directly targets myeloid cell
leukemia 1 (Mcl1) in the primary hepatocytes. A:
Sequence illustration of miR-155 binding site in the
30-untranslated region (UTR) of Mcl1 mRNA. The Mcl1
30-UTR reporter construct with indicated mutation of
the miR-155 binding site was generated. B: Mcl1 30-
UTR luciferase reporter activity in cultured hepato-
cytes transfected with Mcl1 30-UTR reporter construct
(with orwithoutmiR-155binding sitemutation),with
cotransfection of themiR-155mimic or controlmiRNA
mimic. C:Westernblot analysis for Mcl-1. Hepatocytes
from wild-type (WT) and Mir155 knockout (KO) mice
were treated with or without Jo2, and the cell lysates
were obtained for Western blot analysis. The Mcl-1
protein level was quantiﬁed by densitometry anal-
ysis. Data are expressed as means  SD from three
independent experiments (B and C). *P < 0.05,
**P < 0.01. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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Figure 5 Deletion of Mir155 prevents the decrease of myeloid cell
leukemia-1 (Mcl-1). Wild-type (WT) and Mir155 knockout (KO) mice were
i.p. injected with 0.5 mg/g of body weight Jo2 (n Z 8 each group).
Western blot analysis was performed to analyze the expression of Mcl-1 (A)
and Akt/glycogen synthetase kinase (GSK)-3b pathway (B) after 4 hours of
Jo2 injection. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Mir155 Deletion Prevents Liver Injuryobserved in the Mir155 KO livers (Figure 1C). Accordingly,
serum ALT and AST levels were signiﬁcantly higher in
WT mice compared to Mir155 KO mice (Figure 1D). Real-
time quantitative RT-PCR (RT-qPCR) analysis conﬁrmed
absence of miR-155 in Mir155 KO livers; Jo2 treatment
increased miR-155 expression inWT livers by approximately
1.5-fold (P < 0.05) (Figure 1E).
Given that previous studies have shown that miR-155
is implicated in LPS-induced liver inﬂammation,21,22 we
performed further experiments to evaluate whether
Mir155 KO would protect mice against LPS/D-GalNe
induced liver injury. For this approach, WT and Mir155
KO mice were injected i.p. with a single dose of LPS/
D-GalN (25 ng/g body weight LPS in combination
with 600 mg/g body weight of D-GalN). The Mir155 KO
and WT mice showed no signiﬁcant difference in mor-
tality, liver tissue damage, or serum transaminase levels
(Supplemental Figure S1). These ﬁndings demonstrate
that Mir155 deletion is able to ameliorate Fas-induced
hepatocyte apoptosis but not LPS/D-GalNeinduced liver
injury.
Mir155 KO Prevents Fas-Induced Caspase Activation in
the Liver
We next measured liver tissue caspase activities from Jo2-
treated WT and Mir155 KO mice. After Jo2 treatment, the
Mir155 KO mice showed signiﬁcantly lower caspase 3/7,
8, and 9 activities in their livers compared to the WT mice
(Figure 2A). Accordingly, Mir155 KO livers showed
decreased caspase and PARP cleavage compared to the
WT livers (Figure 2B). The numbers of TUNEL-positive
hepatocytes in the Mir155 KO mice were signiﬁcantly
lower compared to the WT mice (Figure 2, C and D).
Immunohistochemical analysis revealed decreased stain-
ing for cleaved caspase-3 in Mir155 KO livers compared
to WT livers (Figure 2E). These ﬁndings demonstrate that
Mir155 KO attenuated Fas-induced caspase activation in
the liver.
Mir155 Deletion Prevents Fas-Induced Apoptosis in
Primary Hepatocytes
To investigate whether deletion of Mir155 could protect
hepatocytes from Fas-induced apoptosis, primary hepato-
cytes were isolated from WT and Mir155 KO mice. We
observed that miR-155 was expressed in WT hepatocytes
but not in Mir155 KO hepatocytes, as determined by RT-
qPCR (Figure 3A). In response to 0.1 mg/mL Jo2 plus 10
mg/mL cycloheximide treatment for 4 hours, the Mir155 KO
hepatocytes exhibited reduced PARP cleavage (Figure 3B),
less nuclear fragmentation (Figure 3, C and D), and reduced
caspase 3/7, 8, and 9 activities in comparison to the WT
hepatocytes (Figure 3E). These ﬁndings demonstrate that
deletion of Mir155 in primary hepatocytes is able to prevent
Fas-induced apoptosis.The American Journal of Pathology - ajp.amjpathol.orgmiR-155 Directly Targets Mcl1 in Primary Hepatocytes
By using a bioinformatics prediction system (http://www.
microrna.org, last accessed November 29, 2014), we
found that mouse Mcl1 30-UTR contained a speciﬁc miR-
155 binding site (Figure 4A). To further determine
whether Mcl1 is directly regulated by miR-155, we
generated reporter constructs containingMcl1 30-UTR with
mutation of the miR-155 binding site (Figure 4A). Primary
hepatocytes isolated from WT mice were then transfected
with the Mcl1 30-UTR reporter construct (with or without
miR-155 site mutation), with cotransfection of the miR-155
mimic or control miRNA mimic. miR-155 mimic repressed
theMcl1 30-UTR luciferase reporter activity by >60%, and
the effect was abolished when the miR-155 binding site
was mutated (Figure 4B). Accordingly, a higher level of
Mcl-1 was observed in Mir155 KO hepatocytes compared
to WT hepatocytes; this phenomenon was observed in he-
patocytes with or without Jo2 treatment (Figure 4C). These
ﬁndings establish Mcl1 as a direct target of miR-155 in
hepatocytes.
Mir155 KO Prevents Mcl-1 Reduction after Jo2
Treatment
We next examined the effect of Fas activation on Mcl-1
protein level in the liver tissues. Although the protein level of
Mcl-1 in the livers of WT mice declined after Jo2 injection,
the level of Mcl-1 was maintained at pre-Jo2 treatment level
in the Mir155 KO mice (Figure 5A). Given that Akt and
GSK-3b are known to regulate Mcl-1 via post-translational
mechanisms,23,24 we further examined the levels of Akt
and GSK-3b proteins in WT and Mir155 KO livers. We
observed that Jo2 treatment decreased Akt and GSK-3b
proteins in both WT and Mir155 KO livers; however, the
levels of Akt and GSK-3b proteins did not signiﬁcantly differ
between WT and Mir155 KO mice (either before or after Jo1039
Figure 6 Knockdown ofmyeloid cell leukemia-1 (Mcl-1) in vivo accelerates Fas-induced apoptosis. Wild-type (WT) andMir155 knockout (KO)mice were injected
with Invivofectamine-Mir155 siRNA complex or Invivofectamine-control siRNA complex via tail vein injection; 48 hours later, the mice were injected with 0.5 mg/g
of body weight Jo2, i.p. (nZ 5 per group). A:Western blot shows decreased Mcl-1 protein level in the liver after Invivofectamine-Mir155 siRNA complex treatment
for 48 hours. Quantiﬁcation of relative Mcl-1 protein level. B: Hematoxylin and eosin staining of the liver tissues. Pretreatment with Mcl1 siRNA exacerbates Fas-
induced liver injury inWTmice andMir155 KOmice compared with corresponding controls. C: Serum alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels in mice with or without Mcl1 siRNA. D: Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate digoxigenin nick-end labeling
(TUNEL) staining of the liver tissues from mice with or without Mcl1 siRNA treatment. Representative images and the quantiﬁcation of TUNEL-positive cells. E:
Immunohistochemical staining of the liver tissues for cleaved caspase-3 from mice with or without Mcl1 siRNA treatment. F: Caspase 3/7, 8, and 9 activities in the
liver tissues from mice with or without Mcl1 siRNA treatment. Data are expressed as means  SD (A and CeE). nZ 3 independent experiments (A and D); nZ 5
(C and E). *P < 0.05, **P < 0.01. Original magniﬁcation, 100 (B and D). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RLU, relative light unit.
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Figure 7 Restoration of Mir155 expression enhances Fas-induced
apoptosis in Mir155 knockout (KO) mice. Eight-week-old Mir155 KO mice
were administrated lentiviral particles containing preemiR-155 (LV-miR-155)
(n Z 3) or lentiviral particles containing scrambled miRNA (LV-scrambled-
miRNA) (nZ 3) by tail vein injection in a volume of 200 mL of sterile saline.
Seven days after lentiviral particle injection, the mice were treated with 0.5
mg/g of body weight Jo2 for 4 hours. A:Hematoxylin and eosin staining of the
liver tissues. B and C: Serum alanine aminotransferase (ALT; B) and aspartate
aminotransferase (AST; C) levels. C: Western blot analysis for the cleavage of
poly (ADP-ribose) polymerase (PARP) and caspases 3, 8, and 9. Data are
expressed asmeans SD. nZ 3 (B). *P< 0.05. Original magniﬁcation,100
(A). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Mir155 Deletion Prevents Liver Injurytreatment) (Figure 5B). Collectively, our ﬁndings support
regulation of Mcl-1 by miR-155 in the liver.
Inhibition of Mcl1 Reverses the Protection against
Fas-Induced Liver Injury in Mir155 KO Mice
To investigate the role of Mcl1 for protection against Fas-
induced liver injury in vivo, we used a siRNA to specif-
ically silence Mcl1 expression in mice. WT and Mir155 KO
mice were pretreated with 7 mg/kg Mcl1 siRNA or 7 mg/kg
siRNA control via tail vein injection, along with Invivofect-
amine 2.0 reagent for optimal delivery to the liver. Forty-eight
hours after the Invivofectamine-siRNA complex injection,
the mice were administrated a single dose of 0.5 mg/g of body
weight Jo2 and the animals were sacriﬁced 4 hours after Jo2
injection to assess the extent of liver injury. The levels of
Mcl-1 protein were successfully reduced by Mcl1 siRNA in
bothWTandMir155KOmice (Figure 6A). Pretreatmentwith
Mcl1 siRNA reversed the protection against Jo2-induced liver
tissue damage inMir155KOmice (Figure 6B), and enhanced
serum ALT and AST levels in bothWT andMir155KOmice
(Figure 6C).Mcl1 siRNA pretreatment led to more prominent
hepatocyte apoptosis, as determined by TUNEL staining
(Figure 6D), cleaved caspase-3 staining (Figure 6E), and
caspase activity assays (Figure 6F) of the liver tissues. These
ﬁndings conﬁrmed the protective role of Mcl-1 in Fas-
induced liver injury in WT mice and also documented the
role of Mcl-1 in resistance to Fas-induced liver injury in
Mir155 KO mice.
Delivery of Mir155 Enhances Fas-Induced Apoptosis in
Mir155 KO Mice
To further evaluate the role of Mir155 in Fas-induced liver
injury, we used lentiviral vector to restoreMir155 expression
in Mir155 KO mice. Speciﬁcally, 8-week-old Mir155 KO
mice were administrated LV-miR-155 or LV-scrambled-
miRNA by tail vein injection. In this system, delivery of
pre-miR-155 or control lentiviral particles did not alter liver
tissue histological features or transaminase levels. Successful
hepatic expression ofMir155 in mice injected with pre-miR-
155 lentiviral particles was conﬁrmed by RT-qPCR analysis
(Supplemental Figure S2). Seven days after virus injection,
themicewere i.p. administered0.5mg/gof bodyweight Jo2 for
4 hours. We observed that LV-miR-155 injection enhanced
Jo2-induced liver injury, as reﬂected by more evident tissues
damage (Figure 7A), higher serum transaminases (Figure 7B),
and more prominent caspase activation/PARP cleavage
(Figure 7C), compared to LV-scrambled control injection.
Thus, delivery of Mir155 to Mir155 KO mice is able to
restore Fas-induced liver injury in vivo.
Discussion
Fas-induced apoptosis is implicated in a wide range of liver
diseases, such as viral hepatitis, alcoholic and nonalcoholicThe American Journal of Pathology - ajp.amjpathol.orgsteatohepatitis, ischemia/reperfusion injury, and fulminant
hepatic liver failure.25e32 Herein, we demonstrate that
Mir155 deletion protects mice against Fas-induced liver
injury, as indicated by the lower mortality, less liver tissue
injury, lower serum ASL and ALT levels, lower caspase
activities, and resistance to hepatocyte apoptosis. The role of
hepatocyte Mir155 is supported by the observation that
hepatocytes isolated from Mir155 KO mice showed1041
Chen et alresistance to Fas-induced apoptosis, in vitro. To our
knowledge, this is the ﬁrst study demonstrating the role of
Mir155 in Fas-induced liver injury and the contribution of
hepatocyte Mir155 to regulation of cell apoptosis and sur-
vival. In addition, our study showed that deletion of Mir155
in mice exhibited no signiﬁcant effect on LPS/D-
GalNeinduced liver injury.
Apoptosis is known to be triggered by the death receptor (or
extrinsic) pathway and the mitochondrial (or intrinsic)
pathway.32 Fas (CD95 or apoptosis antigen-1) is one of the
death receptors that trigger extrinsic apoptotic pathway. Fas
activation results in formation of the death-inducing signaling
complex (DISC) [composed of Fas-associated death domain
(FADD), proecaspase-8, and its regulator c-FLIP], where
proecaspase-8 becomes oligomerized and activated.33e36
The mitochondrial (or intrinsic) pathway is regulated by the
Bcl-2 family of proteins, including the anti-apoptotic mem-
bers (Bcl-2, Bcl-xl, Bcl-w, Mcl-1, A1, and BOO), the pro-
apoptotic members (Bax, Bak, and Bok), and the BH3-only
pro-apoptotic members (Bid, Bim, Bik, Bad, Bmf, Hrk,
Noxa, and Puma).35,37,38 The complex interplay and ratio
between pro-apoptotic and anti-apoptotic Bcl-2 members
determine the propensity of the cell to undergo apoptosis
(characterized by mitochondrial outer membrane per-
meabilizationeinduced release of cytochrome c and activa-
tion of caspase-9).39 In Fas-induced apoptosis, cells can be
divided into type I and type II cells, depending on whether
their death relies on mitochondria40: type I cells die through
Fas-induced apoptosis without the contribution from mito-
chondria (the cells can produce enough amounts of active
caspase-8 at DISC to induce apoptosis), whereas type II cells
produce little active caspase-8 at DISC and need mitochondria
ampliﬁcation of Fas-induced apoptosis.40
Herein, we observed that Fas activation induced the
activation of both extrinsic and intrinsic apoptotic pathways,
as reﬂected by increased caspase 8 and 9 activities in Jo2-
treated liver tissues and cultured hepatocytes. Our obser-
vations are consistent with the documented induction of
both extrinsic and intrinsic apoptotic pathways by Fas
activation.34,40e42 In our system, we observed that deletion
of Mir155 attenuated Fas-induced activation of both cas-
pases 8 and 9 and that the effect is mediated, at least in part,
through up-regulation of Mcl1.
Deregulated miR-155 promotes Fas-mediated apoptosis
in human intervertebral disk degeneration by targeting
FADD and caspase-3.43 miR-155 targets FADD in human
embryonic kidney 293 cells.22 However, our sequence
alignment analysis revealed no miR-155 binding site in
mouse FADD and caspase-3 genes. Our ﬁndings suggest
that miR-155 directly targets Mcl1 in mouse hepatocytes.
The latter assertion is based on the following observations:
i) miR-155 binding site is present in the mouse Mcl1 30-
UTR; ii) miR-155 mimic reduces Mcl1 30-UTR luciferase
reporter activity; iii) mutation of miR-155 binding site
abolished miR-155einduced reduction of Mcl1 30-UTR
reporter activity; and iv) the hepatocytes isolated from1042Mir155 KO mice express higher level of Mcl-1 protein
compared to WT hepatocytes.
Mcl-1 is a crucial anti-apoptotic protein in the Bcl-2 fam-
ily.44e47Hepatocyte-speciﬁc deletion ofMcl1 inmice has been
shown to cause spontaneous induction of apoptosis
and increase the susceptibility to Fas-induced hepatocellular
damage.48 Herein, we observed that inhibition of Mcl-1 exac-
erbated Jo2-induced liver injury, characterized by increased
serum transaminases, increased liver tissue damage, and pro-
nounced hepatocyte apoptosis. Our ﬁndings demonstrate that
Mcl-1 is a key factor thatmediates the protection ofMir155KO
mice against Fas-induced apoptosis.
The current study provides novel evidence for post-
transcriptional regulation of Mcl-1 expression via miR-155
binding to Mcl1 30-UTR. Given that post-translational
modiﬁcation is known to be implicated in the regulation
of Mcl1, we further evaluated this possibility in our system.
Previous studies have shown that GSK-3b can phosphory-
late Mcl-1 at Ser159 site, leading to Mcl-1 degradation via
the ubiquitin-proteasome pathway,23 and that Akt can
phosphorylate and inactivate GSK-3b, leading to Mcl-1
protein accumulation24; these studies led us to examine
the levels of Akt and GSK-3b in WT and Mir155 KO livers
after Jo2 treatment. We observed that hepatic levels of Akt/
GSK-3b proteins did not signiﬁcantly differ between WT
and Mir155 KO mice. These ﬁndings suggest that Akt and
GSK-3b are unlikely to be involved in miR-155emediated
regulation of Mcl-1.
We observed that deletion of Mir155 was able to protect
against Fas- but not LPS/D-GalNeinduced liver injury.
Thus, miR-155 may regulate response depending on the
speciﬁc context of the liver injuries. The observations that
Mcl-1 is a key target of miR-155 in hepatocytes and that
Mcl-1 is imperative for protection against Fas-induced he-
patocyte apoptosis provide a mechanistic explanation for
Mir155 deletionemediated protection against Fas-induced liver
injury. A previous study has established that overexpression
of Mcl-1 is able to protect against tumor necrosis factore
induced hepatocyte apoptosis in vitro and LPS/D-GalNein-
duced liver injury in vivo.49 A separate study shows thatMir155
overexpression sensitizes LPS/D-GalNeinduced injury.22 In
our system, we did not detect liver injury difference in LPS/D-
GalNetreated WT and Mir155 KO mice (Supplemental
Figure S1, AeC). The levels of Mcl-1 protein in the livers
did not signiﬁcantly differ between WT and Mir155 KO mice
after LPS/D-GalN treatment (Supplemental Figure S1D). It is
possible that the lack of protection of Mir155 KO on LPS/D-
GalNeinduced liver injury may relate to the use of D-GalN,
which blocks the hepatic mRNA synthesis and, in turn, abol-
ished the effect ofMir155 loss. Thus, the role ofMir155 in LPS-
induced liver injury remains to be further deﬁned.
In summary, this study provides novel evidence for an
important role of Mir155 in regulation of Fas-induced he-
patocyte apoptosis and liver injury. Mcl1 was identiﬁed as a
bona ﬁde target of miR-155 in hepatocytes. Our ﬁndings
warrant further investigation to explore the intriguingajp.amjpathol.org - The American Journal of Pathology
Mir155 Deletion Prevents Liver Injurypossibility of inhibiting miR-155 for prevention and treat-
ment of liver injuries and liver diseases that involve Fas
activation.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.12.020.
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